Home » Stocks » CRISPR Therapeutics

CRISPR Therapeutics AG (CRSP)

Stock Price: $107.72 USD -2.11 (-1.92%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
After-hours: $108.08 +0.36 (0.33%) Oct 19, 7:55 PM

Stock Price Chart

Key Info

Market Cap 7.56B
Revenue (ttm) 289.15M
Net Income (ttm) 19.58M
Shares Out 70.17M
EPS (ttm) 0.32
PE Ratio 336.63
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $107.72
Previous Close $109.83
Change ($) -2.11
Change (%) -1.92%
Day's Open 111.30
Day's Range 106.70 - 111.81
Day's Volume 980,678
52-Week Range 32.30 - 111.90

More Stats

Market Cap 7.56B
Enterprise Value 6.66B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 70.17M
Float 54.16M
EPS (basic) 0.62
EPS (diluted) 0.32
FCF / Share 0.74
Dividend n/a
Dividend Yield n/a
Earnings Yield 0.30%
FCF Yield 0.60%
Payout Ratio n/a
Shares Short 4.81M
Short Ratio 7.42
Short % of Float 8.88%
Beta 2.30
PE Ratio 336.63
Forward PE n/a
P/FCF Ratio 166.74
PS Ratio 26.14
PB Ratio 7.70
Revenue 289.15M
Operating Income -4.13M
Net Income 19.58M
Free Cash Flow 45.33M
Net Cash 901.15M
Net Cash / Share 12.84
Gross Margin 38.12%
Operating Margin -1.43%
Profit Margin 6.80%
FCF Margin 15.68%
ROA -0.34%
ROE 3.06%
ROIC 24.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (18)

Buy 12
Overweight 0
Hold 4
Underweight 0
Sell 2

Analyst Consensus: Buy

Price Target

$96.20*
(-10.69% downside)
Low
31.0
Current: $107.72
High
140.0
Target: 96.20
*Average 12-month price target from 15 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue2903.1241.005.160.25-
Revenue Growth9169.85%-92.38%693.9%1990.69%--
Gross Profit2903.1241.005.160.25-
Operating Income46.74-159-64.65-68.13-25.73-6.63
Net Income66.86-165-68.36-23.18-25.50-6.26
Shares Outstanding54.3947.9640.0612.265.043.56
Earnings Per Share1.17-3.44-1.71-1.89-5.061.97
Operating Cash Flow56.68-96.24-70.09-52.8659.43-4.79
Capital Expenditures-6.68-2.77-7.81-3.02-1.15-
Free Cash Flow49.99-99.01-77.91-55.8858.27-4.79
Cash & Equivalents9494602433191571.00
Total Debt52.54---38.34-
Net Cash / Debt8964602433191181.00
Assets1,0674892713451591.53
Liabilities12796.8283.511121242.23
Book Value939392188233-29.10-7.12
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name CRISPR Therapeutics AG
Country Switzerland
Employees 304
CEO Samarth Kulkarni

Stock Information

Ticker Symbol CRSP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CRSP
IPO Date October 19, 2016

Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.